Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Ardelyx’s tenapanor has potential to capture a slice of the HP market, says GlobalData

The Food and Drug Administration (FDA) recently issued a Complete Response Letter (CRL) to Ardelyx concerning tenapanor’s New Drug Application (NDA) for chronic kidney disease (CKD)–hyperphosphatemia (HP). If eventually approved, tenapanor has the potential to capture a slice of the HP market by targeting dialysis-dependent patients who are not able to maintain recommended phosphate levels, […]
Read more

Vertex and AbbVie are the only current and future players in the cystic fibrosis market, says GlobalData

The disease-modifying nature of cystic fibrosis transmembrane conductance regulator (CFTR) modulators has transformed the treatment paradigm for cystic fibrosis (CF) over the last decade, a trend that is likely to persist to 2030, and will greatly improve the quality of life and longevity of patients, according to GlobalData. The leading data and analytics company notes […]
Read more

Increased use of virtual trials has contributed to improved patient accrual rates, says GlobalData

The increased use of virtual components such as eConsent, telemedicine, remote patient monitoring and wearables in clinical trials over the past decade has led to fewer trial delays or terminations due to low participant numbers says GlobalData, a leading data and analytics company. According to GlobalData’s report, ‘Virtual Clinical Trials – Thematic Research’, COVID-19 lockdowns […]
Read more

Global hematological cancer market set to grow rapidly across all treatment segments in the next five years, says GlobalData

The hematological cancer therapy market is diverse and highly genericized, with chemotherapies currently accounting for the highest number of marketed drugs. However, the availability of more targeted and innovative therapies means that sales of antibodies, cell therapies and targeted therapies are all set to increase to 2027 at Compound Annual Growth Rates (CAGRs) of 11.5%, […]
Read more

Approval of first interchangeable biosimilar insulin will increase competition with payer contracts, says GlobalData

When it comes to insulin choice, price is currently the biggest barrier, as insulin brand preference is primarily determined not by a doctor, but through payer contracts with pharma companies, according to GlobalData. The leading data and analytics company notes that while patients will be increasingly prescribed Viatris/Biocon’s Semglee (biosimilar insulin glargine-yfgn) over Sanofi’s Lantus […]
Read more

Gene therapies could revolutionize cardiovascular disease management offering a one-time treatment for conditions such as heart failure, says GlobalData

Gene therapies could revolutionize the management of chronic cardiovascular diseases (CVDs) such as heart failure, according to GlobalData. The leading data and analytics company notes that there are currently *87 CVD gene therapies currently in development, and they hold potential to vastly improve patients’ quality of life. Fiona Chisholm, Pharma Analyst at GlobalData comments: “As […]
Read more

Domestic pharma firms lead CAR-T therapy trials in China, says GlobalData

China’s overall focus within oncology research is increasing at a rapid pace. Moreover, the country recently approved its first chimeric antigen receptor (CAR)-T cell therapy. Against this backdrop, Chinese domestic pharma companies are found at the forefront of company-sponsored CAR-T cell therapy trials and are likely to dominate the CAR-T landscape, says GlobalData, a leading […]
Read more

Takeda’s TAK-994 shows potential for orexin agonists as narcolepsy treatment

Takeda Pharmaceutical’s TAK-994 has recently received breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1). The potential approval of TAK-994 could lead to the first treatment that increases orexin activity in patients with narcolepsy, says GlobalData, a […]
Read more

Novel diagnostic face masks that detect SARS-CoV-2 could offer enhanced method to detect and respond to Delta variant, says GlobalData

Following today’s news (18 August) that diagnostic face masks developed by the Massachusetts Institute of Technology (MIT) and Harvard University are about to be commercialized: Sultan Ahmed, Infectious Disease Analyst at GlobalData, a leading data and analytics company, offers his view: “GlobalData believes that the new diagnostic masks have the potential to create a large […]
Read more

COVID-19 booster doses will help protect against variants, but will drive global vaccination inequality, says GlobalData

Following the news that the US government is planning to recommend COVID-19 booster doses for all residents eight months after full vaccination; Philipp Rosenbaum, PhD, Senior Healthcare Analyst at GlobalData, a leading data and analytics company, offers his view: “Initial data from Pfizer/BioNTech, Moderna, AstraZeneca, and Novavax shows that a third dose of a COVID-19 […]
Read more

Takeda leads the way among Big Pharma players in microbiome-targeting treatments, says GlobalData

Takeda is currently developing multiple microbiome-targeting agents through a number of collaborations with innovative small companies. Its latest partnership with Finch Therapeutics to advance FIN-524, a microbiome-targeting drug candidate for the treatment of ulcerative colitis (UC), into clinical development under the new name TAK-524, demonstrates Takeda’s commitment to pursuing novel microbiome-targeting therapeutic approaches in the […]
Read more

Bimekizumab new results in psoriasis pave way for potential best in class, says GlobalData

UCB, a global biopharmaceutical company, has recently presented new interim data from BE BRIGHT, an open-label extension (OLE) trial of an interleukin (IL)-17A/F inhibitor ‘bimekizumab’ for plaque psoriasis (PsO), at the 2021 American Academy of Dermatology (AAD) Summer Meeting. While the data are still preliminary, they strongly support a potential approval for bimekizumab in PsO […]
Read more

Australia set to reinforce cancer research with committed funding and research collaborations, says GlobalData

Cancer remains the leading cause of death in Australia. Against this backdrop, the government is supporting the home-grown oncology research with committed funding. Moreover, the research collaborations between the Australian institutes and pharma companies will further help expedite the overall research developments, says GlobalData, a leading data and analytics company. In June 2021, Australia announced […]
Read more

NK cell therapies promising and potentially available off-the-shelf for hematological and solid tumor treatment, says GlobalData

Natural killer (NK) cell therapies have the potential to be an effective, off-the-shelf treatment for a wide range of cancers. Analysis of NK cell therapies, currently in development, reveals that 57% of these are allogeneic therapies, and although development in hematological indications is more advanced, there are a high number of therapies being investigated in […]
Read more
1 … 57 58 59 60 61 … 108